Please login to the form below

Not currently logged in
Email:
Password:

Paul Navarre moves from Allergan to Ferring Pharmaceuticals

Takes up CEO role at its Ferring Holding subsidiary

Paul NavarreFerring Pharmaceuticals has appointed Paul Navarre as CEO of Ferring Holding Inc - a subsidiary of Ferring Pharmaceuticals, a privately owned, international pharma company - in a role that will see him assume responsibility for all of the group’s activities including commercial operations, clinical development and manufacturing.

Navarre has more than 25 years’ experience in the pharmaceuticals and consumer good industries and joins from Allergan, where he was president of Allergan International and managed a $3bn speciality care business covering dermatology, ophthalmology, urology and neurosciences.

Before joining Allergan, Navarre spent 15 years at Procter & Gamble holding positions in France, USA, Switzerland, Italy and the UK.

He said: “Ferring is a fast growing pharmaceutical company with a unique culture centred on people and patients.

“I am very excited to lead this organisation into the next phase of its development.”

As CEO, Navarre will report to the board of directors chaired by Michel Pettigrew, president of the executive board and chief operating officer of Ferring Group.

Pettigrew said: “Paul’s extensive pharmaceutical speciality care experience and proven international leadership skills will help him take our successful US operations to the next level, pursuing our rapid extension.”

Navarre succeeds Aaron Graff who has been appointed to a global role as executive vice president, chief commercial officer and member of the Ferring Group executive board.

6th June 2017

From: Sales

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Pegasus

Pegasus inspires healthy decisions through creative, inspirational and integrated communications. Working with ambitious clients, we deliver big ideas and far-reaching...

Latest intelligence

Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
The heavy toll of COVID-19 on cancer patients
We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...

Infographics